Finasteride Shortage: What Providers and Prescribers Need to Know in 2026

As the prescribing landscape for finasteride has expanded — driven largely by the explosion of telehealth platforms offering hair loss treatment — providers in urology, dermatology, and primary care are fielding increasing patient inquiries about access and availability. This briefing summarizes the 2026 supply situation, prescribing implications, available alternatives, and practical tools to support your patients.

Supply Status: No National Shortage, But Local Gaps Are Common

As of early 2026, finasteride is not listed on the FDA Drug Shortages database or the ASHP drug shortage list. Multiple generic manufacturers — including Teva, Dr. Reddy's, and Hetero Labs — produce both 1 mg and 5 mg strengths, and the national supply chain is stable.

However, providers and their clinical staff are likely aware that patients frequently report difficulty filling prescriptions at their local pharmacy. This is a pharmacy-level inventory issue driven by:

Telehealth demand growth: Platforms like Hims, Ro, and Roman have dramatically increased finasteride 1 mg prescriptions, outpacing some retail pharmacy stocking habits.

Insurance non-coverage for alopecia: Because most commercial plans and Medicare do not cover finasteride for androgenetic alopecia (cosmetic indication), many pharmacies do not prioritize high inventory of the 1 mg dose. This creates a gap between demand and stocking.

Generic manufacturer preferences: Pharmacy wholesale contracts favor specific generic manufacturers. Temporary supply hiccups from one manufacturer result in localized stock-outs even when other manufacturers have adequate supply.

Key 2025 Regulatory Update: EMA Confirms Suicidal Ideation Risk

In 2025, the European Medicines Agency (EMA) confirmed that suicidal thoughts can occur as a side effect of finasteride and dutasteride, primarily in patients taking the 1 mg dose for androgenetic alopecia. The EMA initiated this review in October 2024 due to post-marketing safety signals. The FDA is monitoring this issue separately through its MedWatch post-marketing surveillance system.

Clinical recommendation: Screen patients starting finasteride for hair loss for depression, anxiety, and mood disorders at baseline. Counsel patients about this risk and establish a follow-up check within the first 3 months of therapy. Document this counseling in the patient record.

Prescribing Considerations for Hair Loss Patients in 2026

Document indication clearly: Most insurance plans do not cover finasteride for androgenetic alopecia. Prescribing for BPH (if clinically indicated) may improve fill rates and reduce patient cost burden.

Counsel on timeline expectations: 3+ months required before visible benefit; up to 12 months for maximum effect. Hair loss resumes within 12 months of discontinuation.

PSA monitoring: Finasteride reduces PSA by approximately 50% after 6 months. Establish a new PSA baseline at least 6 months after initiating therapy. Inform any provider conducting PSA monitoring that the patient is on finasteride to avoid misinterpretation.

Discuss sexual side effects proactively: Decreased libido, erectile dysfunction, and ejaculation disorders are reported by ~2–4% of patients in clinical trials. Some patients report persistent sexual dysfunction after discontinuation (post-finasteride syndrome). Shared decision-making and documented consent is advisable.

Prescribing Considerations for BPH Patients in 2026

Combination therapy: For moderate-to-severe BPH with prostate volume > 30 mL, AUA guidelines support combination therapy with finasteride + an alpha-blocker (e.g., doxazosin, tamsulosin). Jalyn (dutasteride + tamsulosin) is a single-pill combination alternative.

Alpha-blocker bridging: If a BPH patient cannot fill finasteride, a short-term alpha-blocker (tamsulosin, terazosin) may bridge symptoms. Alpha-blockers provide faster symptom relief but do not reduce prostate size or prevent long-term progression.

Dutasteride substitution: If finasteride 5 mg is consistently unavailable, dutasteride 0.5 mg is a direct therapeutic alternative for BPH. It is FDA-approved, widely available as generic, and has a similar efficacy profile. Note the significantly longer half-life (~5 weeks) when counseling on side effects.

Tools to Help Your Patients Access Finasteride

One of the most common calls your clinical staff receives from finasteride patients is "I can't find it at my pharmacy." Medfinder for Providers is a service that calls pharmacies near your patient to identify which ones have finasteride in stock. Rather than triaging these calls or having patients work through a phone list, you can direct them to medfinder to handle the search.

Additional patient-facing resources:

GoodRx coupons — finasteride as low as $9.25 for a 30-day supply of generic 1 mg

Mark Cuban Cost Plus Drugs — transparent pricing for finasteride, ships by mail

NeedyMeds — for patients who need income-based patient assistance

Summary for Prescribers

No national finasteride shortage in 2026 — supply is stable

Local stock-outs are common, especially for 1 mg (hair loss indication)

2025 EMA warning on suicidal ideation warrants baseline mental health screening for alopecia patients

Dutasteride is the most straightforward alternative for both BPH and off-label hair loss if finasteride is unavailable

Direct patients to medfinder to locate nearby pharmacies with finasteride in stock

For a companion patient-access guide, see: How to Help Your Patients Find Finasteride in Stock: A Provider's Guide.